Ginkgo Bioworks operates a horizontal synthetic-biology platform that programs cells and microbes for customers across pharmaceuticals, agriculture, industrial chemicals, and other bio-based applications. Clients use its foundry and code-base model to design, build, and test engineered organisms rather than building full wet-lab stacks in-house. The business is technology- and services-led, with revenue tied to platform partnerships and programs more than to a single end product.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 39.1 | — | -60.3 | — |
| Q3 2025 | 38.8 | — | -80.8 | — |
| Q4 2025 | 33.4 | — | -80.8 | — |
| Q1 2026 | 19.5 | — | -82.6 | — |
| Q2 2026 | 20.2 | -48.5% | -46.7 | — |
All markets — KeepWinning global stock screener
Other companies on NYSE: BitGo Holdings, Inc. (BTGO), Third Coast Bancshares, Inc. (TCBX), Chatham Lodging Trust (CLDT), Cannae Holdings, Inc. (CNNE), Babcock & Wilcox Enterprises, Inc. (BW), Mistras Group, Inc. (MG)